Incyte Corporation (INCY) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Incyte Corporation (INCY) Profile & Business Summary
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Key Information
| Ticker | INCY |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.incyte.com |
Market Trend Overview for INCY
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-10-13 (ET)
As of 2026-10-13, INCY is showing signs of slowing down. Over the longer term, the trend remains bullish.
INCY last closed at 108.62. The price is about 0.8 ATR below its recent average price (111.68), and the market is currently in a trend that may be losing strength. Price at 108.62 is near minor support around 103.75. Momentum may slow, while minor resistance sits near 122.69. View Support & Resistance from Options
Short-term weakness is unfolding within a broader uptrend, suggesting a pullback rather than a full trend reversal.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear key risk boundary right now.
On 2026-08-28, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model sees a bearish edge, but still treats it as a selective downside setup rather than an aggressive downside call.
Up probability is only 42.9%, with predictability at 47% and agreement at 93%. Reversal risk is 18%, while reward/risk stands at -0.19. That suggests downside pressure is present, while the setup still remains selective rather than extreme.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 58 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-10-13. The current price is 108.62, 10.72% below the estimated average cost of 121.66. An estimated 1.7% of recent positioning is below the current price, while 97.9% is above it. The peak-density price is 123.40. The largest concentrated cost region is 121.35 to 125.05 and contains 27.7% of the estimated distribution. The nearest region below the current price is 108.45 to 108.55. The nearest region above the current price is 112.65 to 113.75.
Short Interest & Covering Risk for INCY
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is above its usual range, suggesting rising pressure on short positions, though not yet extreme. (Historical percentile: 69%)
Structure Analysis
INCY Short positioning looks normal. Current days to cover is 6.1 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. Price is already trending lower (20D return -10.8%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-09-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.